NASDAQ:IDYA

IDEAYA Biosciences Competitors

$19.55
+0.31 (+1.61 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.15
Now: $19.55
$19.98
50-Day Range
$17.76
MA: $21.48
$24.83
52-Week Range
$4.74
Now: $19.55
$24.92
Volume175,803 shs
Average Volume216,637 shs
Market Capitalization$643.31 million
P/E RatioN/A
Dividend YieldN/A
Beta2.11

Competitors

IDEAYA Biosciences (NASDAQ:IDYA) Vs. ALXO, ITCI, RCUS, LGND, CYRX, and ZNTL

Should you be buying IDYA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to IDEAYA Biosciences, including ALX Oncology (ALXO), Intra-Cellular Therapies (ITCI), Arcus Biosciences (RCUS), Ligand Pharmaceuticals (LGND), Cryoport (CYRX), and Zentalis Pharmaceuticals (ZNTL).

ALX Oncology (NASDAQ:ALXO) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Insider and Institutional Ownership

73.5% of ALX Oncology shares are held by institutional investors. Comparatively, 62.3% of IDEAYA Biosciences shares are held by institutional investors. 20.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares ALX Oncology and IDEAYA Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ALX OncologyN/AN/AN/A
IDEAYA BiosciencesN/A-28.83%-22.92%

Earnings and Valuation

This table compares ALX Oncology and IDEAYA Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALX OncologyN/AN/AN/AN/AN/A
IDEAYA BiosciencesN/AN/A$-41,970,000.00($3.36)-5.82

Analyst Recommendations

This is a summary of recent recommendations for ALX Oncology and IDEAYA Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ALX Oncology00703.00
IDEAYA Biosciences00703.00

ALX Oncology presently has a consensus price target of $90.6667, indicating a potential upside of 44.70%. IDEAYA Biosciences has a consensus price target of $32.2222, indicating a potential upside of 64.82%. Given IDEAYA Biosciences' higher probable upside, analysts plainly believe IDEAYA Biosciences is more favorable than ALX Oncology.

Summary

ALX Oncology beats IDEAYA Biosciences on 3 of the 5 factors compared between the two stocks.

Intra-Cellular Therapies (NASDAQ:ITCI) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Insider & Institutional Ownership

79.1% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 62.3% of IDEAYA Biosciences shares are held by institutional investors. 18.2% of Intra-Cellular Therapies shares are held by company insiders. Comparatively, 20.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Intra-Cellular Therapies and IDEAYA Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intra-Cellular Therapies-1,985.32%-48.27%-42.56%
IDEAYA BiosciencesN/A-28.83%-22.92%

Valuation & Earnings

This table compares Intra-Cellular Therapies and IDEAYA Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intra-Cellular Therapies$60,000.0041,024.92$-147,720,000.00($2.68)-11.35
IDEAYA BiosciencesN/AN/A$-41,970,000.00($3.36)-5.82

IDEAYA Biosciences has lower revenue, but higher earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Intra-Cellular Therapies and IDEAYA Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intra-Cellular Therapies00703.00
IDEAYA Biosciences00703.00

Intra-Cellular Therapies currently has a consensus target price of $47.4286, indicating a potential upside of 55.91%. IDEAYA Biosciences has a consensus target price of $32.2222, indicating a potential upside of 64.82%. Given IDEAYA Biosciences' higher probable upside, analysts clearly believe IDEAYA Biosciences is more favorable than Intra-Cellular Therapies.

Volatility & Risk

Intra-Cellular Therapies has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500.

Summary

IDEAYA Biosciences beats Intra-Cellular Therapies on 7 of the 11 factors compared between the two stocks.

Arcus Biosciences (NYSE:RCUS) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Volatility & Risk

Arcus Biosciences has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500.

Insider & Institutional Ownership

60.6% of Arcus Biosciences shares are held by institutional investors. Comparatively, 62.3% of IDEAYA Biosciences shares are held by institutional investors. 19.7% of Arcus Biosciences shares are held by company insiders. Comparatively, 20.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Arcus Biosciences and IDEAYA Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcus Biosciences00903.00
IDEAYA Biosciences00703.00

Arcus Biosciences currently has a consensus target price of $51.50, indicating a potential upside of 48.41%. IDEAYA Biosciences has a consensus target price of $32.2222, indicating a potential upside of 64.82%. Given IDEAYA Biosciences' higher probable upside, analysts clearly believe IDEAYA Biosciences is more favorable than Arcus Biosciences.

Valuation & Earnings

This table compares Arcus Biosciences and IDEAYA Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcus Biosciences$15 million163.96$-84,710,000.00($1.93)-17.98
IDEAYA BiosciencesN/AN/A$-41,970,000.00($3.36)-5.82

IDEAYA Biosciences has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Arcus Biosciences and IDEAYA Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcus Biosciences-112.63%-27.43%-20.96%
IDEAYA BiosciencesN/A-28.83%-22.92%

Summary

IDEAYA Biosciences beats Arcus Biosciences on 7 of the 12 factors compared between the two stocks.

IDEAYA Biosciences (NASDAQ:IDYA) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Risk & Volatility

IDEAYA Biosciences has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

Institutional & Insider Ownership

62.3% of IDEAYA Biosciences shares are held by institutional investors. 20.7% of IDEAYA Biosciences shares are held by insiders. Comparatively, 10.6% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for IDEAYA Biosciences and Ligand Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IDEAYA Biosciences00703.00
Ligand Pharmaceuticals01602.86

IDEAYA Biosciences presently has a consensus price target of $32.2222, indicating a potential upside of 64.82%. Ligand Pharmaceuticals has a consensus price target of $215.60, indicating a potential upside of 45.70%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe IDEAYA Biosciences is more favorable than Ligand Pharmaceuticals.

Earnings & Valuation

This table compares IDEAYA Biosciences and Ligand Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IDEAYA BiosciencesN/AN/A$-41,970,000.00($3.36)-5.82
Ligand Pharmaceuticals$120.28 million20.44$629.30 million$2.1170.13

Ligand Pharmaceuticals has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IDEAYA Biosciences and Ligand Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IDEAYA BiosciencesN/A-28.83%-22.92%
Ligand Pharmaceuticals-11.23%5.90%3.22%

Summary

IDEAYA Biosciences beats Ligand Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

IDEAYA Biosciences (NASDAQ:IDYA) and Cryoport (NASDAQ:CYRX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Risk & Volatility

IDEAYA Biosciences has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.

Institutional & Insider Ownership

62.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 88.3% of Cryoport shares are held by institutional investors. 20.7% of IDEAYA Biosciences shares are held by insiders. Comparatively, 11.5% of Cryoport shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for IDEAYA Biosciences and Cryoport, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IDEAYA Biosciences00703.00
Cryoport00703.00

IDEAYA Biosciences presently has a consensus price target of $32.2222, indicating a potential upside of 64.82%. Cryoport has a consensus price target of $72.00, indicating a potential upside of 35.82%. Given IDEAYA Biosciences' higher possible upside, equities research analysts clearly believe IDEAYA Biosciences is more favorable than Cryoport.

Earnings & Valuation

This table compares IDEAYA Biosciences and Cryoport's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IDEAYA BiosciencesN/AN/A$-41,970,000.00($3.36)-5.82
Cryoport$33.94 million71.23$-18,330,000.00($0.55)-96.38

Cryoport has higher revenue and earnings than IDEAYA Biosciences. Cryoport is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IDEAYA Biosciences and Cryoport's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IDEAYA BiosciencesN/A-28.83%-22.92%
Cryoport-55.87%-17.68%-11.32%

Summary

Cryoport beats IDEAYA Biosciences on 6 of the 11 factors compared between the two stocks.

IDEAYA Biosciences (NASDAQ:IDYA) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Institutional & Insider Ownership

62.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 67.1% of Zentalis Pharmaceuticals shares are held by institutional investors. 20.7% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for IDEAYA Biosciences and Zentalis Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IDEAYA Biosciences00703.00
Zentalis Pharmaceuticals00703.00

IDEAYA Biosciences presently has a consensus price target of $32.2222, indicating a potential upside of 64.82%. Zentalis Pharmaceuticals has a consensus price target of $57.00, indicating a potential upside of 2.06%. Given IDEAYA Biosciences' higher possible upside, equities research analysts clearly believe IDEAYA Biosciences is more favorable than Zentalis Pharmaceuticals.

Earnings & Valuation

This table compares IDEAYA Biosciences and Zentalis Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IDEAYA BiosciencesN/AN/A$-41,970,000.00($3.36)-5.82
Zentalis PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares IDEAYA Biosciences and Zentalis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IDEAYA BiosciencesN/A-28.83%-22.92%
Zentalis PharmaceuticalsN/AN/AN/A

Summary

Zentalis Pharmaceuticals beats IDEAYA Biosciences on 3 of the 5 factors compared between the two stocks.


IDEAYA Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ALX Oncology logo
ALXO
ALX Oncology
1.9$62.66+7.4%$2.51 billionN/A0.00Insider Selling
News Coverage
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$30.42+3.7%$2.46 billion$60,000.00-9.45Analyst Revision
News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.8$34.70+2.2%$2.46 billion$15 million-18.17News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$147.98+2.8%$2.46 billion$120.28 million-149.47Decrease in Short Interest
News Coverage
Cryoport logo
CYRX
Cryoport
1.7$53.01+1.5%$2.42 billion$33.94 million-91.40
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.4$55.85+2.3%$2.29 billionN/A0.00Analyst Report
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.81+0.0%$2.28 billion$963.01 million14.23
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$28.86+1.8%$2.20 billion$23.90 million-17.93Analyst Report
Insider Selling
Analyst Revision
News Coverage
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$27.06+0.8%$2.08 billion$103.54 million-20.35
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$129.29+0.7%$2.07 billionN/A-11.68
Amarin logo
AMRN
Amarin
1.6$5.19+1.9%$2.04 billion$429.76 million-103.78Upcoming Earnings
MacroGenics logo
MGNX
MacroGenics
1.2$33.66+0.1%$2.02 billion$64.19 million-10.75Upcoming Earnings
Analyst Report
Insider Selling
Unusual Options Activity
News Coverage
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.80+1.1%$1.98 billion$410,000.00-6.04
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.87+3.3%$1.98 billionN/A-19.65Unusual Options Activity
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$61.37+4.4%$1.96 billionN/A-26.11
FibroGen logo
FGEN
FibroGen
1.8$21.12+0.3%$1.94 billion$256.58 million-8.09
Generation Bio logo
GBIO
Generation Bio
1.6$34.29+8.0%$1.93 billionN/A0.00Gap Up
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.70+1.0%$1.90 billion$34.51 million-17.69
Kura Oncology logo
KURA
Kura Oncology
1.6$28.45+1.1%$1.88 billionN/A-17.45News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$26.00+2.1%$1.86 billion$26.87 million-13.61Analyst Report
MORF
Morphic
1.3$56.44+2.1%$1.83 billion$16.98 million-36.18Insider Selling
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05+0.0%$1.77 billion$970,000.000.00News Coverage
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00+0.0%$1.77 billion$14.87 million-14.18
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$19.48+2.3%$1.77 billionN/A-6.93Analyst Downgrade
Increase in Short Interest
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.81+0.4%$1.74 billion$428.41 million15.67Analyst Upgrade
Unusual Options Activity
News Coverage
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.5$37.30+4.8%$1.74 billionN/A0.00Analyst Upgrade
Insider Selling
News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.70+1.9%$1.71 billion$1.63 billion13.90
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$24.40+2.1%$1.68 billion$2.34 million-10.34
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.30+0.3%$1.66 billion$392.76 million12.99Analyst Upgrade
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$18.08+0.4%$1.65 billion$145.97 million-7.32
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.62+1.3%$1.61 billion$320,000.00-8.59
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.00+0.0%$1.59 billionN/A0.00
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.76+2.3%$1.55 billion$82.27 million-18.93
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.2$34.57+3.2%$1.55 billionN/A0.00
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$43.28+4.1%$1.53 billionN/A0.00
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$30.57+1.0%$1.52 billionN/A-3.31Analyst Upgrade
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$24.95+3.7%$1.51 billion$175.34 million-14.68Insider Selling
uniQure logo
QURE
uniQure
1.7$32.96+1.8%$1.48 billion$7.28 million-8.74Insider Selling
Unusual Options Activity
Keros Therapeutics logo
KROS
Keros Therapeutics
1.4$63.02+1.5%$1.47 billionN/A0.00Gap Up
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$36.08+3.4%$1.44 billionN/A-150.33Earnings Announcement
Analyst Downgrade
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$33.09+4.1%$1.44 billion$6.20 million-14.51Gap Down
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.83+2.9%$1.42 billion$73.41 million-4.62News Coverage
Gap Up
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.77+1.6%$1.39 billion$4.23 million-19.83Analyst Report
News Coverage
OLMA
Olema Pharmaceuticals
1.6$34.15+3.1%$1.37 billionN/A0.00
Endo International logo
ENDP
Endo International
1.5$5.90+1.2%$1.36 billion$2.91 billion-8.68
Cara Therapeutics logo
CARA
Cara Therapeutics
1.8$27.13+3.2%$1.35 billion$19.89 million-12.80
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$29.35+4.9%$1.29 billion$230,000.00-13.65News Coverage
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$21.15+5.3%$1.29 billion$59.70 million-211.50News Coverage
Kronos Bio logo
KRON
Kronos Bio
1.7$22.94+4.4%$1.29 billionN/A0.00Insider Selling
Gap Down
Zymeworks logo
ZYME
Zymeworks
1.8$27.76+0.2%$1.28 billion$29.54 million-7.36
This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.